2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Clinical Procedures, Treatment Considerations, Combination Therapy, Supportive Care, Biological Therapies, Non-Biological Therapies, Chemotherapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Immune Mechanism, Molecular Biology, Clinical Practice (Health Services and Quality), Patient Safety, Practice Models, Value, Diseases, Bleeding and Clotting, Immunology, Infectious Diseases, Fungal, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

1613 Time from diagnosis to treatment in the myelomatch precision medicine initiative

Mitchell Sabloff, MSc, MDCM, FRCPC, Megan Othus, PhD2, Eric Stephen Winer, MD3, Jessica Kaplan Altman, MD4, Sarit E. Assouline, MDCM, MSc, FRCPC5, Ehab Atallah, MD6, Konuralp Bayrak7, Uma Borate, MBBS, MSc8, Xueyan Chen, MD, PhD9, Harry P. Erba, MD10, Min Fang, MD, PhD, FACMG11, Sayak Ghatak12, Steven Gore, MD13, Lyndsay Harris, MD14, Annie Im, MD15, Brian A Jonas, MD, PhD16, Curtis Lachowiez, MD17, Richard F. Little, MD18, Mark R. Litzow, MD19, Sanam Loghavi, MD20, Selina Luger, MD, FRCPC21, Laura C Michaelis, MD22, Anna Moseley, MS23, Olatoyosi Odenike Jr, MD24, Afaf Osman, MD25, Xiaoyu QU, PhD, FACMG26, Jerald Radich, MD27, John L Reagan, MD28, Ntasha Roy, MBBS, MHA29, Mary Lynn Savoie, MD, FRCPC30, Richard M. Stone, MD31, Stephanie B Tsai, MD32, Geoffrey L. Uy, MD33, Brent L. Wood, PhD, MD34, Cecilia CS Yeung, MD, Professor Pathology35, Shahanawaz Jiwani, MBBS, PhD36
1 Division of Hematology, Department of Medicine, University of Ottawa and The Ottawa Hospital Research Institute, Ottawa, Canada, Ottawa, Ontario, Canada
2 SWOG Statistics and Data Management Center, Seattle, Washington, United States
3 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
4 Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
5 Jewish General Hospital, Montréal, Quebec, Canada
6 Division of Hematology & Oncology Medical College of Wisconsin, Wisconsin, Wisconsin, United States
7 Department of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania, United States
8 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
9 Translational Science and Therapeutics, Fred Hutchinson Cancer Center, Seattle, Washington, United States
10 Duke University School of Medicine, Durham, North Carolina, United States
11 Translational Science & Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States
12 Division of Pathology and Laboratory Medicine, Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
13 Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, United States
14 Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, United States
15 Department of Malignant Hematology and Medical Oncology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
16 Division of Malignant Hematology/Cellular Therapy and Transplantation, Department of Internal Medicine, University of California Davis School of Medicine, Sacramento, California, United States
17 Division of Hematology/Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon, United States
18 National Cancer Institute, Cancer Therapy Evaluation Program, Bethesda, Maryland, United States
19 Mayo Clinic Comprehensive Cancer Center, Rochester, Minnesota, United States
20 Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houtson, Texas, United States
21 Abramson Cancer Center University of Pennsylvania, Philadelphia, Pennsylvania, United States
22 Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin, United States
23 SWOG Statistics and Data Management Center, Seattle, Washington, United States
24 Section of Hematology/Oncology The University of Chicago, Chicago, Illinois, United States
25 University of Utah Health, Salt Lake City, Utah, United States
26 Fred Hutchinson Cancer Center, Seattle, Washington, United States
27 Translational Science & Therapeutics Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
28 Brown University Health Cancer Institute, The Warren Alpert Medical School of Brown University, Providence, Rhode Island, United States
29 Children’s Hospital Los Angeles, Los Angeles, California, United States
30 University of Calgary, Arthur Child Comprehensive Cancer Centre, Calgary, Alberta, Canada
31 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
32 Hematopoietic Stem Cell Transplant Program Division of Hematology-Oncology Loyola University Medical Center, Maywood, Illinois, United States
33 Division of Oncology, Washington University School of Medicine, Saint Louis, Missouri, United States
34 Childrens Hospital Los Angeles, Los Angeles, California, United States
35 University of Washington School of Medicine, Seattle, Washington, United States
36 Molecular Characterization Laboratory, Clinical Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States

Introduction: As therapy for acute myeloid leukemia (AML) continues to evolve with the introduction of targeted agents, the need to wait for results of the genetic profile (cytogenetic and molecular [the bottleneck to initiate treatment]) has become increasingly important.  Waiting for the genetic profile, though, can lead to delays in starting treatment while patients are hospitalized. MyeloMATCH (MM) is an NCI-sponsored initiative for AML and myelodysplastic syndrome (MDS) employing a Master Screening and Reassessment Protocol (MSRP) to assign patients (pts) to a disease biology-specific clinical trial (MM sub-study) [NCT05564390]. A crucial step of trial eligibility is central lab analysis of the genetic profile. One of the goals of the framework study is to deliver the genetic profile result within 72 hours in order to proceed to sub-study assignment without any further avoidable delays. We sought to analyze the process from diagnosis to treatment initiation within the MM framework study to assess the timelines, determine any modifiable causes of treatment delay and evaluate potential interventions to improve efficiency.

Methods:   After pts with suspected AML or MDS consent for the MSRP, blood and marrow are sent to the MM Molecular Diagnostics Network (MDNet) of central CLIA labs operating under a single Investigational Device Exemption (IDE) to rapidly define the genetic profile.  These data are catalogued online (MATCHBox) by a bioinformatics team. Once the biologic profile (disease genetics, cytogenetics, and immunophenotype) and the local pathology report are received from the local institution, they are reviewed for confirmation of diagnosis and preliminary study eligibility.  The verification team, consisting of oncologists, laboratorians and informaticians, meets daily to review and assign participants to an appropriate sub-study. The treatment center then receives an email with sub-study assignment after which they can initiate registration to that trial.

Results: As of April 3, 2026, 1000 pts have been enrolled in the MSRP from 103 sites (United States (n=95), Puerto Rico (n=2) and Canada (n=6)).

In all eligible patients with samples received for diagnostic screening for MM (n=911), the median time to obtain the complete biologic profile results after sample receipt at the MDNet laboratories was 71 hours (3 days). The median time for results of cytogenetics and NGS were 70 and 47 hours, respectively. 1% had completed results by <24 hours, 6% within 48 hours, 54% within 72 hours, and 89% within 96 hours.

The total time from registration (roughly equivalent to the time of the diagnostic bone marrow) to assignment to an MM sub-study by the verification team is 6.1 [IQR 5.0-8.0] days. Time from registration to receipt of all required data (local pathology is usually the last piece of data to be received), just prior to sub-study assignment is 5.9 [IQR 4.9-7.8] days. Time from receipt of the samples at the MDNet laboratories to receipt of all the pathology data from the site is 4.1 [IQR 3.1-5.9] days. The median time from receipt of samples to assignment to an MM sub-study is 4.9 [IQR 4.0-6.0] days. Once all the data are received from the local site the assignment takes a median of 3 [IQR 0.6-4.0] hours. Receipt of local pathology takes a day longer on average than assay results for sub-study assignment.

Conclusions: In order to shorten the time from diagnosis to treatment the MM framework sought to decrease the assessment of the genetic profile (often the most time-consuming part in the timeline) which has been successfully achieved. This has permitted a more rapid assignment to an MM sub-study within the framework. The time from the diagnostic bone marrow to assignment to an MM sub-study may be further decreased if the local pathology reports were received in tandem with the genetic profile results permitting assignment to a MM sub-study without further delay, speeding up the process by about a day. Through the alignment of several cooperative groups the MM framework study has been successfully improving the diagnostic process of patients with AML and MDS permitting the rapid assessment to available therapies.

Mitchell Sabloff, MSc, MDCM, FRCPC: Jazz Pharmaceuticals - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); Servier - Consultancy (Includes expert testimony)